U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H27N9O7S2
Molecular Weight 593.636
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFTERAM PIVOXIL

SMILES

[H][C@]12SCC(CN3N=NC(C)=N3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C(=O)OCOC(=O)C(C)(C)C

InChI

InChIKey=UIYAXIPXULMHAI-JLGRZTKVSA-N
InChI=1S/C22H27N9O7S2/c1-10-26-29-30(27-10)6-11-7-39-18-14(25-16(32)13(28-36-5)12-8-40-21(23)24-12)17(33)31(18)15(11)19(34)37-9-38-20(35)22(2,3)4/h8,14,18H,6-7,9H2,1-5H3,(H2,23,24)(H,25,32)/b28-13-/t14-,18-/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H27N9O7S2
Molecular Weight 593.636
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Cefteram is a semisynthetic cephalosporin formulated for oral administration as the prodrug ester, cefteram pivoxil. The mechanism of action of cefteram is inhibition of bacterial cell wall synthesis. Cefteram exerts its bactericidal activity by strongly binding to penicillin-binding protein (PBP) 3, 1A, and 1Bs. The drug is available in Japan and is used for the treatment of bacterial infections.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TOMIRON

Approved Use

To treat pharyngitis/laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, and secondary infections in chronic respiratory lesion; cystitis, pyelonephritis and urethritis; bartholinitis, intrauterine infection and uterine adnexitis; otitis media and sinusitis; periodontitis, pericoronitis and gnathitis
PubMed

PubMed

TitleDatePubMed
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites.
1986 Jun
In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.
1987 Jul
Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.
1987 Sep
Patents

Sample Use Guides

The usual adult dosage for oral use is 150 − 600 mg (potency) of cefteram pivoxil daily in 3 divided doses after meals.
Route of Administration: Oral
The activity of cefteram was compared with that of other P-lactams against a total of 491 bacterial strains. The drug was highly active (MIC for 90% of the strains tested [MIC90] < 2 ug/ml) against the majority of the members of the family Enterobacteriaceae, Haemophilus influenzae, Neisseria spp., and Streptococcuspneumoniae, being at least 16-fold more active than cephalexin and 8-fold more active than cefuroxime. There was no activity against Pseudomonas aeruginosa, Enterobacter sp., and Citrobacter sp. Staphylococcus aureus was moderately susceptible to cefteram (MIC90, 8 ug/ml).
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:42:44 UTC 2023
Edited
by admin
on Sat Dec 16 05:42:44 UTC 2023
Record UNII
0OD86RT58C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFTERAM PIVOXIL
MART.   WHO-DD  
Common Name English
CEFTERAM PIVALOYLOXYMETHYL ESTER
MI  
Common Name English
Cefteram pivoxil [WHO-DD]
Common Name English
T-2588
Code English
PIVALOYLOXYMETHYL (Z)-7-(2-(2-AMINOTHIAZOL-4-YL)-2-METHOXYIMINOACETAMIDO)-3-(5-METHYL-2H-TETRAZOL-2-YLMETHYL)-3-CEPHEM-4-CARBOXYLATE
Common Name English
CEFTERAM PIVALOYLOXYMETHYL ESTER [MI]
Common Name English
RO 19-5248
Code English
ANTIBIOTIC T 2588
Code English
CEFTERAM PIVOXIL [MART.]
Common Name English
T 2588
Code English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2Z)-2-(2-AMINO-4-THIAZOLYL)-2-(METHOXYIMINO)ACETYL)AMINO)-3-((5-METHYL-2H-TETRAZOL-2-YL)METHYL)-8-OXO-, (2,2-DIMETHYL-1-OXOPROPOXY)METHYL ESTER, (6R,7R)-
Common Name English
RO-19-5248
Code English
TOMIRON
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL2105953
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
MESH
C046817
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
NCI_THESAURUS
C98230
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
EVMPD
SUB01135MIG
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
DRUG CENTRAL
560
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
CAS
82547-81-7
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
EPA CompTox
DTXSID401316612
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
SMS_ID
100000084702
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
MERCK INDEX
m3219
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY Merck Index
FDA UNII
0OD86RT58C
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
PUBCHEM
5362114
Created by admin on Sat Dec 16 05:42:44 UTC 2023 , Edited by admin on Sat Dec 16 05:42:44 UTC 2023
PRIMARY
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
Does not undergo extensive metabolism. Excretion in urine. Can lead to depletion of carnitine.
Related Record Type Details
ACTIVE MOIETY